Gout drug trial design
Executive Summary
FDA's Arthritis Advisory Committee will discuss trial design and endpoints for gout on Nov. 13. Several agents are in development for gout, including Merck's Arcoxia (etoricoxib), TAP/Teijin's xanthine oxidase inhibitor febuxostat (TMX-67) and Savient's Puricase (rPEG-uricase). The meeting will be held at the Marriott Washingtonian Center in Gaithersburg, Md. at 8 a.m. [To 1sign up for a webcast, visit FDAAdvisoryCommittee.com]...